This article first appeared on GuruFocus .
Release Date: August 11, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Second-quarter revenue increased 199% year-over-year to $452,000, with product revenue up 347% to $447,000.
-
Gross profit surged 388% to $278,000, and gross margin improved to approximately 62% from 38% a year ago.
-
Received purchase orders from multiple contract manufacturing customers exceeding $3.2 million, providing commercial visibility into 2027.
-
SINAPTIC Foot and Ankle Osteotomy Wedge System achieved FDA 510(k) clearance and first clinical use, with initial commercial revenue recognized.
-
Completed financing transactions generating approximately $5 million in gross proceeds, including a private placement and ATM sales, with $5.1 million remaining ATM capacity.
Negative Points
-
Substantial doubt remains regarding the company's ability to continue as a going concern, with only $3.6 million in cash at quarter end.
-
Net loss widened to $2.7 million in Q2 2026, up from $2.3 million in the prior-year quarter.
-
Operating expenses increased 16% to $3.2 million, driven by higher G&A and sales and marketing costs.
-
Cash used in operating activities rose to $5.3 million in the first half of 2026, up from $3.7 million a year ago.
-
Revenue guidance for Q3 and Q4 2026 is modest ($900K-$1.1M and $1M-$1.3M, respectively) and subject to significant uncertainty.
Q & A Highlights
Q: What were the key financial results for the second quarter of 2026, and what drove the improvements? A: (Eric Olson, CEO) Second-quarter revenue increased 199% year-over-year to $452,000, with product revenue up 347% to $447,000. Gross profit increased 388% to $278,000, and gross margins improved to approximately 62% from 38% a year ago. The improvements were driven by higher product sales, improved pricing on certain OEM products, a favorable sales mix, and early commercial sales of the SINAPTIC Osteotomy Foot and Ankle Wedge System.
Q: Can you elaborate on the company's liquidity position and the going concern disclosure? A: (Eric Olson, CEO) On June 30, we had approximately $3.6 million in cash and cash equivalents and $4.8 million in stockholders' equity. We completed financing transactions generating approximately $5 million in gross proceeds during the quarter. However, substantial doubt remains regarding our ability to continue as a going concern, and we do not minimize that disclosure. Our responsibility is to increase revenue, manage operating and working capital requirements, pursue cost actions, and access capital prudently.
Q: What is the status of the contract manufacturing business and the announced purchase orders? A: (Eric Olson, CEO) Product revenue growth was driven primarily by increased sales in our OEM industrial manufacturing business. In June, we announced purchase orders from multiple existing customers with an aggregate value exceeding $3.2 million. Production and shipment activities have begun and will continue into 2027. The milestones that matter are qualified production, manufacturing yield, quality release, on-time shipment, customer acceptance, recognized revenue, and repeat orders. We will distinguish clearly between order value and recognized revenue.
Q: What are the company's revenue expectations for the remainder of 2026? A: (Kevin Trask, CFO) Based on current production schedules and customer requirements, we expect total revenue to be approximately $900,000 to $1.1 million in the third quarter and approximately $1 million to $1.3 million in the fourth quarter of 2026. These expectations are subject to significant uncertainty, particularly with respect to production timing, customer scheduling, and manufacturing execution.
Q: How is the SINAPTIC Foot and Ankle Wedge System commercialization progressing? A: (Eric Olson, CEO) The system received FDA 510(k) clearance in late 2025, and the first wedges were used in a reconstructive procedure in March 2026, with initial commercial revenue recognized during our limited use review. We are focused on building adoption through surgeon education, channel development, and product availability. We are evaluating the most capital-efficient routes to market, including direct-to-surgeon engagement, distributor relationships, and broader strategic relationships.
Q: Can you explain the changes in operating expenses, particularly the decline in R&D expense? A: (Kevin Trask, CFO) Total operating expenses increased 16% to $3.2 million. R&D expense decreased 54% to $573,000, primarily due to the reallocation of approximately $700,000 of overhead costs to general and administrative expense. G&A expense increased 64% to $2.3 million, reflecting higher headcount costs, non-cash stock-based compensation, and the overhead reallocation. Sales and marketing expense increased to $273,000 due to commercial headcount and launch-related activity for SINAPTIC.
Q: What is the company's strategy for its proprietary silicon nitride medical platform? A: (Eric Olson, CEO) The business model is built around two complementary sources of value: contract manufacturing and OEM activities for near-term revenue, and the proprietary silicon nitride medical platform for differentiated products and potential OEM licensing, distribution, and strategic partnership opportunities. We are prioritizing programs based on time to revenue, required capital, regulatory pathways, and partner interest. We have engaged Board member Chris Lyons and his company, Southern Metrics, to help coordinate and evaluate inbound strategic opportunities.
Q: What were the key balance sheet changes during the quarter? A: (Kevin Trask, CFO) Inventory increased to $2.3 million from $1 million at year-end, reflecting purchases and production activity to support anticipated customer demand. Net cash used in operating activities was $5.3 million for the first six months of 2026, compared with $3.7 million in the prior-year period. Net cash provided by financing activities was $4.8 million, including net proceeds from the June private placement and ATM sales. As of June 2026, we had approximately $5.1 million of remaining capacity under the ATM program.
Q: How is management addressing the cost structure relative to the current revenue base? A: (Eric Olson, CEO) The current cost structure is highly relative to our revenue base, and we recognize that. Management is evaluating staffing, outside services, facilities, project priorities, and working capital through the lens of commercial return and strategic value. Our goal is not simply to reduce spending in isolation but to deploy capital where it can support revenue conversion, customer delivery, medical adoption, or transactions that improve the company's long-term position.
Q: What are the company's priorities for the remainder of 2026? A: (Eric Olson, CEO) Our priorities are straightforward: first, execute the contract manufacturing orders already in hand with quality, timing, and working capital discipline; second, build a disciplined commercial foundation for the SINAPTIC wedge system; third, concentrate capital and management attention on programs and strategic relationships with a credible path to revenue or funded development; and fourth, continue aligning spending, staffing, inventory, and financing decisions with the milestones most likely to create value for shareholders.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
